Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology Journal Article
| Authors: | Prockop, D. J.; Prockop, S. E.; Bertoncello, I. |
| Article Title: | Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology |
| Abstract: | The cells referred to as mesenchymal stem/progenitor cells (MSCs) are currently being used to treat thousands of patients with diseases of essentially all the organs and tissues of the body. Strikingly positive results have been reported in some patients, but there have been few prospective controlled studies. Also, the reasons for the beneficial effects are frequently unclear. As a result there has been a heated debate as to whether the clinical trials with these new cell therapies are too far ahead of the science. The debate is not easily resolved, but important insights are provided by the 60-year history that was required to develop the first successful stem cell therapy, the transplantation of hematopoietic stem cells. The history indicates that development of a dramatically new therapy usually requires patience and a constant dialogue between basic scientists and physicians carrying out carefully designed clinical trials. It also suggests that the field can be moved forward by establishing better records of how MSCs are prepared, by establishing a large supply of reference MSCs that can be used to validate assays and compare MSCs prepared in different laboratories, and by continuing efforts to establish in vivo assays for the efficacy of MSCs. Stem Cells 2014;32:3055-3061 |
| Keywords: | cancer chemotherapy; cancer risk; nonhuman; antineoplastic agent; t lymphocyte; anemia; dendritic cell; embryonic stem cell; radiotherapy; bisphosphonic acid derivative; stem cell transplantation; hematopoietic stem cell transplantation; cancer therapy; b lymphocyte; cytokine; acute leukemia; engraftment; thymus; acetylsalicylic acid; heart failure; prostaglandin e2; irradiation; thalassemia; graft versus host reaction; hematopoietic cell; hematopoietic stem cells; fibroblast; umbilical cord blood; mesenchymal stem cell; teratoma; rheumatoid arthritis; clinical effectiveness; pluripotent stem cell; bone marrow cell; osteoclast; osteoporosis; hematopoietic stem cell; immunity; indoleamine 2,3 dioxygenase; corticosteroid; bone marrow transplantation; growth factor; lymphocyte; stem cell niche; hydroxyapatite; science; sildenafil; hematologic disease; aplastic anemia; hematology; cell adhesion molecule; spleen cell; critically ill patient; tissue culture; medical history; clinical trial (topic); sickle cell anemia; cartilage cell; angina pectoris; endothelial progenitor cell; synovium; umbilical cord; tissue typing; prostaglandin synthase; dilution; pyrophosphate; osteogenesis imperfecta; salicylic acid derivative; feeder cell; human; article; spleen transplantation; cortisone; need for scientific dialogue; new clinical therapies; adenosine triphosphatase (potassium sodium); digitalis; hypocalcin; germline stem cell |
| Journal Title: | Stem Cells |
| Volume: | 32 |
| Issue: | 12 |
| ISSN: | 1066-5099 |
| Publisher: | AlphaMed Press |
| Date Published: | 2014-12-01 |
| Start Page: | 3055 |
| End Page: | 3061 |
| Language: | English |
| DOI: | 10.1002/stem.1806 |
| PROVIDER: | scopus |
| PMCID: | PMC4245369 |
| PUBMED: | 25100155 |
| DOI/URL: | |
| Notes: | Export Date: 2 January 2015 -- Source: Scopus |
